Epiphany Biosciences' Mission is to develop new therapeutics and
diagnostic technologies that treat or prevent the spread of diseases of
viral origin. To support this mission, Epiphany has assembled a truly
world-class team of virologists, clinicians, and drug development
Epiphany is a
privately-held company located in San Francisco. The company raised $36
million in a Series A financing in March 2007.
More about Valomaciclovir (EPB-348)
Valomaciclovir is a late-stage, next-generation novel herpes drug
with broad-spectrum antiviral activity. Valomaciclovir has demonstrated
potent activity and efficacy against the Varicella Zoster Virus (VZV)
that causes shingles and the Epstein-Barr Virus (EBV) that causes infectious mononucleosis.
Both a Phase 2b clinical study of Valomaciclovir for the treatment of shingles and a Phase
2 study of Valomaciclovir for the treatment of acute infectious mononucleosis
have been successfully completed.
More about Shingles >>
More about Infectious Mononucleosis >>